Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100487032> ?p ?o ?g. }
- W2100487032 endingPage "64" @default.
- W2100487032 startingPage "64" @default.
- W2100487032 abstract "To identify blood donors with occult hepatitis B virus (HBV) infection (OBI) to promote safe blood donation.Descriptive cross sectional study was conducted on 3167 blood donors negative for hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV Ab) and human immunodeficiency virus Ab. They were subjected to the detection of alanine aminotransferase (ALT) and aspartate transaminase (AST) and screening for anti-HBV core antibodies (total) by two different techniques; [Monoliza antibodies to hepatitis B core (Anti-HBc) Plus-Bio-Rad] and (ARC-HBc total-ABBOT). Positive samples were subjected to quantitative detection of antibodies to hepatitis B surface (anti-HBs) (ETI-AB-AUK-3, Dia Sorin-Italy). Serum anti-HBs titers > 10 IU/L was considered positive. Quantitative HBV DNA by real time polymerase chain reaction (PCR) (QIAGEN-Germany) with 3.8 IU/mL detection limit was estimated for blood units with negative serum anti-HBs and also for 32 whose anti-HBs serum titers were > 1000 IU/L. Also, 265 recipients were included, 34 of whom were followed up for 3-6 mo. Recipients were investigated for ALT and AST, HBV serological markers: HBsAg (ETI-MAK-4, Dia Sorin-Italy), anti-HBc, quantitative detection of anti-HBs and HBV-DNA.525/3167 (16.6%) of blood units were positive for total anti-HBc, 64% of those were anti-HBs positive. Confirmation by ARCHITECT anti-HBc assay were carried out for 498/525 anti-HBc positive samples, where 451 (90.6%) confirmed positive. Reactivity for anti-HBc was considered confirmed only if two positive results were obtained for each sample, giving an overall prevalence of 451/3167 (14.2%) for total anti-HBc. HBV DNA was quantified by real time PCR in 52/303 (17.2%) of anti-HBc positive blood donors (viral load range: 5 to 3.5 x 10(5) IU/mL) with a median of 200 IU/mL (mean: 1.8 x 10(4) ± 5.1 x 10(4) IU/mL). Anti-HBc was the only marker in 68.6% of donors. Univariate and multivariate logistic analysis for identifying risk factors associated with anti-HBc and HBV-DNA positivity among blood donors showed that age above thirty and marriage were the most significant risk factors for prediction of anti-HBc positivity with AOR 1.8 (1.4-2.4) and 1.4 (1.0-1.9) respectively. Other risk factors as gender, history of blood transfusion, diabetes mellitus, frequent injections, tattooing, previous surgery, hospitalization, Bilharziasis or positive family history of HBV or HCV infections were not found to be associated with positive anti-HBc antibodies. Among anti-HBc positive blood donors, age below thirty was the most significant risk factor for prediction of HBV-DNA positivity with AOR 3.8 (1.8-7.9). According to HBV-DNA concentration, positive samples were divided in two groups; group one with HBV-DNA ≥ 200 IU/mL (n = 27) and group two with HBV-DNA < 200 IU/mL (n = 26). No significant difference was detected between both groups as regards mean age, gender, liver enzymes or HBV markers. Serological profiles of all followed up blood recipients showed that, all were negative for the studied HBV markers. Also, HBV DNA was not detected among studied recipients, none developed post-transfusion hepatitis (PTH) and the clinical outcome was good.OBI is prevalent among blood donors. Nucleic acid amplification/HBV anti core screening should be considered for high risk recipients to eliminate risk of unsafe blood donation." @default.
- W2100487032 created "2016-06-24" @default.
- W2100487032 creator A5001572445 @default.
- W2100487032 creator A5002020430 @default.
- W2100487032 creator A5009311562 @default.
- W2100487032 creator A5014260315 @default.
- W2100487032 creator A5016032356 @default.
- W2100487032 creator A5025512373 @default.
- W2100487032 creator A5032897150 @default.
- W2100487032 creator A5039633915 @default.
- W2100487032 creator A5048533697 @default.
- W2100487032 creator A5053685635 @default.
- W2100487032 creator A5064658652 @default.
- W2100487032 date "2013-01-01" @default.
- W2100487032 modified "2023-10-16" @default.
- W2100487032 title "Occult hepatitis B virus infection among Egyptian blood donors" @default.
- W2100487032 cites W1492485283 @default.
- W2100487032 cites W1527879934 @default.
- W2100487032 cites W1532619498 @default.
- W2100487032 cites W1938307711 @default.
- W2100487032 cites W1975262686 @default.
- W2100487032 cites W1979932795 @default.
- W2100487032 cites W1983466682 @default.
- W2100487032 cites W1984153699 @default.
- W2100487032 cites W1991253504 @default.
- W2100487032 cites W1996090282 @default.
- W2100487032 cites W1997337133 @default.
- W2100487032 cites W2000242859 @default.
- W2100487032 cites W2010307710 @default.
- W2100487032 cites W2010969938 @default.
- W2100487032 cites W2017016952 @default.
- W2100487032 cites W2020500293 @default.
- W2100487032 cites W2023142763 @default.
- W2100487032 cites W2028768606 @default.
- W2100487032 cites W2042421842 @default.
- W2100487032 cites W2054968660 @default.
- W2100487032 cites W2054999512 @default.
- W2100487032 cites W2056349256 @default.
- W2100487032 cites W2072052013 @default.
- W2100487032 cites W2073260968 @default.
- W2100487032 cites W2077452793 @default.
- W2100487032 cites W2078862516 @default.
- W2100487032 cites W2080104847 @default.
- W2100487032 cites W2080222370 @default.
- W2100487032 cites W2081449747 @default.
- W2100487032 cites W2090099466 @default.
- W2100487032 cites W2096779282 @default.
- W2100487032 cites W2096974907 @default.
- W2100487032 cites W2096996627 @default.
- W2100487032 cites W2099786144 @default.
- W2100487032 cites W2103769998 @default.
- W2100487032 cites W2108539255 @default.
- W2100487032 cites W2108661232 @default.
- W2100487032 cites W2112996757 @default.
- W2100487032 cites W2116942634 @default.
- W2100487032 cites W2123335423 @default.
- W2100487032 cites W2124459409 @default.
- W2100487032 cites W2139344413 @default.
- W2100487032 cites W2142369750 @default.
- W2100487032 cites W2143130283 @default.
- W2100487032 cites W2145796783 @default.
- W2100487032 cites W2150141117 @default.
- W2100487032 cites W2151169883 @default.
- W2100487032 cites W2151690311 @default.
- W2100487032 cites W2152088134 @default.
- W2100487032 cites W2161962640 @default.
- W2100487032 cites W2164785916 @default.
- W2100487032 cites W2166441700 @default.
- W2100487032 cites W2168252998 @default.
- W2100487032 cites W2322257439 @default.
- W2100487032 doi "https://doi.org/10.4254/wjh.v5.i2.64" @default.
- W2100487032 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3642725" @default.
- W2100487032 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23646231" @default.
- W2100487032 hasPublicationYear "2013" @default.
- W2100487032 type Work @default.
- W2100487032 sameAs 2100487032 @default.
- W2100487032 citedByCount "43" @default.
- W2100487032 countsByYear W21004870322013 @default.
- W2100487032 countsByYear W21004870322014 @default.
- W2100487032 countsByYear W21004870322015 @default.
- W2100487032 countsByYear W21004870322016 @default.
- W2100487032 countsByYear W21004870322017 @default.
- W2100487032 countsByYear W21004870322018 @default.
- W2100487032 countsByYear W21004870322019 @default.
- W2100487032 countsByYear W21004870322020 @default.
- W2100487032 countsByYear W21004870322021 @default.
- W2100487032 countsByYear W21004870322022 @default.
- W2100487032 countsByYear W21004870322023 @default.
- W2100487032 crossrefType "journal-article" @default.
- W2100487032 hasAuthorship W2100487032A5001572445 @default.
- W2100487032 hasAuthorship W2100487032A5002020430 @default.
- W2100487032 hasAuthorship W2100487032A5009311562 @default.
- W2100487032 hasAuthorship W2100487032A5014260315 @default.
- W2100487032 hasAuthorship W2100487032A5016032356 @default.
- W2100487032 hasAuthorship W2100487032A5025512373 @default.
- W2100487032 hasAuthorship W2100487032A5032897150 @default.
- W2100487032 hasAuthorship W2100487032A5039633915 @default.
- W2100487032 hasAuthorship W2100487032A5048533697 @default.